symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
SLRX,0.735,1.138668,59550,2676451,0,0.605-4.44,0.0395,"Salarius Pharmaceuticals, Inc.",USD,0001615219,US79400X1072,79400X107,NASDAQ Capital Market,NASDAQ,Biotechnology,https://www.salariuspharma.com,"Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.",Mr. David J. Arthur M.B.A.,Healthcare,US,12,832 834 6992,2450 Holcombe Boulevard,Houston,TX,77021,0.346242,2.76624,https://financialmodelingprep.com/image-stock/SLRX.png,2015-01-29,False,False,True,False,False
